World Influenza Vaccines Market 2011-2021

  • February 2011
  • -
  • Visiongain

Are you looking for influenza vaccine market data - answers to benefit your work? Our new report shows you revenue prospects for the manufacture and sale of influenza vaccines from 2009 to 2021. 

There, you will see commercial opportunities for influenza vaccines - original research, data and opinions. By ordering now, you can stay ahead. We aim to save you time and aid your decisions.

Our report shows revenue opportunities at world, company, product and national levels. You can assess the high growth potential of the influenza vaccine industry and market now.
 
Which influenza market areas will grow fastest this decade? What are the technological and commercial trends to watch? How will national and world markets for influenza vaccines perform from 2011 to 2021?

Our study answers those questions and others for the influenza vaccines market. We show you where the industry is heading from 2011 - events, technologies and revenues. 

What are leading companies doing, and how is competition shaping up? You will see trends in influenza vaccine research and development.

Our new report shows you developments to watch, including multivalent vaccines, faster, more flexible manufacturing, emerging markets and pediatric vaccines.

You can assess the influenza industry's strengths, weaknesses, trends and revenue prospects from 2011. You will see opportunities for influenza vaccine products. 

Here, you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Respond now to get that information.
 
Analysis and expert opinion to help your work - so you won't be left behind

Our new report gives you revenue forecasts, growth rates, market share analysis, SWOT analysis, an R&D review and expert opinion. We include 132 tables and charts and four interviews (shown in the accompanying lists). 

World Influenza Vaccines Market 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:
• You will receive hard data for the influenza vaccine industry - especially our revenue forecasts to 2021
• You will discover sales trends for the overall market and its main components from 2009 to 2021 - seeing where commercial growth will occur
• You will find revenue forecasts for leading products and companies from 2011 to 2021, with discussions of market potential and competition
• You will find revenue forecasts for leading national markets from 2011 to 2021 (US, Japan, UK, Germany, France, Spain, Italy, China and India)
• You will receive influenza vaccine production, distribution, pricing and coverage data
• You will learn how the influenza vaccines industry can change from 2011 to 2021
• You will assess leading companies in influenza vaccines, discovering their activities, outlook and revenue prospects
• You will investigate competition and opportunities influencing the influenza vaccine industry from 2011 onwards
• You will see what stimulates and restrains the industry and market - from the present onwards - including national and international policy
• You will review influenza vaccine technologies, assessing R&D potential
• You will investigate commercial requirements - with therapeutic needs and commercial opportunities discussed
• You will analyse opportunities for established companies and those seeking to enter the market
• You will view expert opinion from our survey, including full interview transcripts.

That combination of quantitative and qualitative market analysis sets our report apart. We give you original market predictions, found only in our work.

You can order our new report, receiving the market information you need

Our report can benefit everybody interested in the manufacture, sale and distribution of influenza vaccines. You will see where the industry is heading, assessing the opp

Table Of Contents

Table of Contents

1. Executive Summary
1.1 Influenza Vaccines Market Review
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Introduction to Influenza and its Treatment
2.1 What is Influenza?
2.2 What is the Social and Economic Burden?
2.3 Who are at Risk?
2.4 How does Influenza Spread?
2.5 Symptoms of Influenza
2.6 About the Influenza Virus
2.6.1 Antigenic Drift
2.6.2 Antigenic Shift
2.7 Seasonal Influenza Epidemic
2.8 How is Influenza Diagnosed?
2.9 Treatment of Influenza
2.9.1 Use of Antiviral Agents 
2.9.2 Vaccination
2.9.2.1 Seasonal Influenza Vaccines
2.9.2.2 Pandemic Influenza Vaccines
2.9.2.3 'Pre-Pandemic' Influenza Vaccines
2.10 Types of Influenza Vaccine
2.10.1 Trivalent Inactivated Vaccines (TIV)
2.10.2 Trivalent Live Attenuated Influenza Vaccine (LAIV)
2.11 Methods of Vaccine Production
2.11.1 Egg-Based Manufacturing Technology
2.11.2 Cell-Based Manufacturing Technology
2.11.2.1 MCDK (Madin Darby Canine Kidney Cells)
2.11.2.2 Vero Cells
2.11.2.3 Per C6 Cells
2.11.3 Cell-Based Technique has an Edge over Egg-Based Vaccine Production
2.11.4 Steps Involved in Vaccine Production
2.11.5 Distribution of Vaccine
2.12 Influenza Pandemics - The New Threat
2.12.1 Increasing Global Vaccine Access to Combat Pandemic Influenza
2.12.2 Government Policy Regarding Pandemic Influenza Vaccines in the Mature Markets

3. The Influenza Vaccine Market - Global, Mature and Emerging
3.1 Challenges of the Global Influenza Vaccine Market
3.2 The Global Influenza Market Worth $4.3bn in 2009
3.3 The Global Market Projected to Grow to 2021
3.4 The Mature Market Projected to Maintain Steady Growth
3.5 The Emerging and Other Markets Projected to Expand Rapidly
3.6 The Growth Rate of the Emerging and Other Market Category Projected to be the Highest

4. Analysis of the Leading Players in the Influenza Vaccines Market
4.1 Influenza Vaccine Sales Estimate for Sanofi Pasteur
4.1.1 Fluzone/Vaxigrip
4.1.2 Investing in Building Capacity
4.2 Novartis Influenza Vaccines Sales to 2021 
4.2.1 Fluvirin
4.3 GlaxoSmithKline PLC 
4.3.1 GSK's Acquisition of ID Biomedical
4.3.2 Fluviral/FluLaval
4.3.3 Fluarix
4.3.4 Key Contracts Announced by GSK to Date
4.4 Other Manufacturers in the Mature Markets
4.4.1 Sales Forecasts for Influvac, Flumist and Inflexal
4.5 The Top Players are Building Global Manufacturing Capacities
4.6 The Key Players are Increasing Manufacturing Capacity in the Emerging Markets

5. Analysis of Mature Markets - the US, Japan, Germany, France, Italy, Spain and the UK
5.1 The Mature Market Predicted to Grow Steadily to 2021
5.1.1 Most of the Global Manufacturing Capacity is in the Developed Countries
5.2 EU5 - UK, Germany, France, Spain and Italy
5.2.1 Growth Rates of UK, Germany, France, Spain and Italy Predicted to Remain Steady
5.2.2 Vaccine Coverage Rates Differ Widely Across Target Groups and Countries in the EU 
5.2.2.1 Strong Governmental Policies would Help to Achieve the WHO Objectives 
5.2.2.2 The GP is at the Centre of the System in France
5.2.2.3 Increasing Influenza Vaccine Coverage: Funding for Regional Authorities in Italy
5.2.2.4 Enhancing Awareness in Germany
5.3 The United States
5.3.1 The Influenza Vaccines Market in the US is Expected to Grow to 2021
5.3.2 Sanofi Pasteur is the Market Leader in the US
5.3.3 Seasonal Influenza Vaccine Supply in US
5.3.4 Vaccine Coverage Rate in the US 
5.3.4.1 Vaccine Coverage among Adults in the US
5.3.4.2 Favourable Reimbursement Schemes have Helped Increase Vaccination Rates
5.3.4.3 US Influenza Vaccine Prices Start to Drop
5.4 Japan
5.4.1 The Influenza Vaccine Market Expected to Grow in Japan
5.4.2 Low Vaccine Coverage Rates in Japan
5.4.3 Influenza Vaccine Prices in Japan
5.4.4 Regional Manufacturers Le

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...

Global Depression Therapy & Treatment Market - Depression drugs and devices, Anxiety Disorders,  SSRIs, Fischer wallace stimulator, Transcranial magnetic stimulation, Psychoanalysis, Cognitive Behavior, Psychodynamic, Electroconvulsive Pipeline Analysis,

Global Depression Therapy & Treatment Market - Depression drugs and devices, Anxiety Disorders,  SSRIs, Fischer wallace stimulator, Transcranial magnetic stimulation, Psychoanalysis, Cognitive Behavior, Psychodynamic, Electroconvulsive Pipeline Analysis,

  • $ 7 000
  • Industry report
  • November 2014
  • by Occams

Depression is a state of emotion that affects thoughts, actions and often, sleeping patterns of affected individual. Depression affects behavior in terms of loss of appetite, being in a constant state ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.